Chengdu Kanghong Pharmaceutical Group said in a statement that it has signed equity acquisition documents with IOPtima Ltd., an Israeli Ophthalmic medical instrument company, concluding a US$47.62 million deal in early October, Yicai.com reported. Chengdu Kanghong will obtain the Israeli firm’s exclusive distribution rights of its IOPtiMate TM surgical system for the treatment of Glaucoma. […]
Thank you for registering!
An account was already registered with this email. Please check your inbox for an authentication link.